Phase II Study to Evaluate Efficacy of Rechallenge With Sunitinib in Patients With Metastatic Pancreatic Neuroendocrine Tumor (pNETs) Well Differentiated G1/2 Advanced or Metastatic Who Previously Failed to Sunitinib.
Phase of Trial: Phase II
Latest Information Update: 30 Nov 2017
At a glance
- Drugs Sunitinib (Primary)
- Indications Pancreatic cancer
- Focus Therapeutic Use
- Acronyms RESUNET
- 24 Nov 2017 Status changed from not yet recruiting to recruiting.
- 22 Mar 2016 New trial record